These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 6711816)

  • 1. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.
    Wagner JL; Hugli TE
    Anal Biochem; 1984 Jan; 136(1):75-88. PubMed ID: 6711816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaphylatoxin generation in multisystem organ failure.
    Heideman M; Hugli TE
    J Trauma; 1984 Dec; 24(12):1038-43. PubMed ID: 6334754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete primary structure of human C4a anaphylatoxin.
    Moon KE; Gorski JP; Hugli TE
    J Biol Chem; 1981 Aug; 256(16):8685-92. PubMed ID: 6167582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylatoxin levels in human vitreous humor.
    Mondino BJ; Sidikaro Y; Sumner H
    Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
    Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaphylatoxin generation and distribution during in vitro LDL apheresis.
    Parusel M; Kadar JG; Borberg H
    Infusionsther Transfusionsmed; 1992 Oct; 19(5):245-8. PubMed ID: 1288769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylatoxin formation in extracorporeal circuits.
    Chenoweth DE
    Complement; 1986; 3(3):152-65. PubMed ID: 3492330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of anaphylatoxin concentrations in suction blisters in patients with psoriasis.
    Ohkohchi K; Takematsu H; Tagami H
    J Invest Dermatol; 1986 Jul; 87(1):65-7. PubMed ID: 3487596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in type 1 human diabetes.
    Sundsmo JS; Papin RA; Wood L; Hirani S; Waldeck N; Buckingham B; Kershnar A; Ascher M; Charles MA
    Clin Immunol Immunopathol; 1985 May; 35(2):211-25. PubMed ID: 3907907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
    Gerard C; Hugli TE
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C4a: the third anaphylatoxin of the human complement system.
    Gorski JP; Hugli TE; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5299-302. PubMed ID: 291947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of human serum complement with allergens. I. Generation of C3a, C4a, and C5a and induction of human neutrophil aggregation.
    Nagata S; Glovsky MM
    J Allergy Clin Immunol; 1987 Jul; 80(1):24-32. PubMed ID: 3496373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
    Janatova J
    Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.